Mengxin Xu

Mengxin Xu

Auto-generated profile, based on publicly available information

Mengxin Xu

Peking University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2024 in Cancer Discovery
Verified
Journal Article
Open access
ZKZiren Kong
Ziren Kong
ZLZhu Li
Zhu Li
XCXi-Yang Cui
Xi-Yang Cui
JWJian Wang
Jian Wang
MXMengxin Xu
Mengxin Xu
SLShaoyan Liu
Shaoyan Liu
Medullary thyroid carcinoma (MTC) can only be cured through the excision of all metastatic lesions, but current clinical practice fails to localize the disease in 29% to 60% of patients. Previously, we developed a fibroblast activation protein inhibitor (FAPI)-based covalent targeted radioligand (CTR) for improved detection sensitivity and accuracy. In this first-in-class clinical trial, we head-to-head compared [68Ga]Ga-CTR-FAPI PET-CT and [18F]fluorodeoxyglucose ([18F]FDG) PET-CT in 50 patients with MTC. The primary endpoint was the patient-based detection rate, with [68Ga]Ga-CTR-FAPI exhibiting higher detection than [18F]FDG (98% vs. 66%, P = 0.0002). This improved detection was attributed to increased tumor uptake (maximum standardized uptake value = 11.71 ± 9.16 vs. 2.55 ± 1.73, P < 0.0001). Diagnostic accuracy, validated on lesions with gold-standard pathology, was greater for [68Ga]Ga-CTR-FAPI compared with [18F]FDG (96.7% vs. 43.3%, P < 0.0001). Notably, the management of 32% of patients was altered following [68Ga]Ga-CTR-FAPI PET-CT, and the surgical plan was changed for 66.7% of patients. Overall, [68Ga]Ga-CTR-FAPI PET-CT provided superior detection and diagnostic accuracy compared with [18F]FDG PET-CT, enabling precision management of patients with MTC. Significance: In this first-in-class clinical trial of CTR, [68Ga]Ga-CTR-FAPI demonstrated an improved patient-based detection rate (98%), tumor uptake (maximum standardized uptake value = 11.71 ± 9.16), and pathology-validated diagnostic accuracy (96.7%) compared with the currently approved method in MTC treatment. It directly altered management in 32% of patients, enabling precision diagnosis and management of MTC. See related commentary by Witney, p. 264


17 June 2026
Verified
Other
Open access
PDF file
ZKZiren Kong
Ziren Kong
ZLZhu Li
Zhu Li
XCXi-Yang Cui
Xi-Yang Cui
JWJian Wang
Jian Wang
MXMengxin Xu
Mengxin Xu
SLShaoyan Liu
Shaoyan Liu
Notification to Attending Physician

17 June 2026
Verified
Other
Open access
PDF file
ZKZiren Kong
Ziren Kong
ZLZhu Li
Zhu Li
XCXi-Yang Cui
Xi-Yang Cui
JWJian Wang
Jian Wang
MXMengxin Xu
Mengxin Xu
SLShaoyan Liu
Shaoyan Liu
Presurgical imaging identification of the 60 lesions

17 June 2026
Verified
Other
Open access
PDF file
ZKZiren Kong
Ziren Kong
ZLZhu Li
Zhu Li
XCXi-Yang Cui
Xi-Yang Cui
JWJian Wang
Jian Wang
MXMengxin Xu
Mengxin Xu
SLShaoyan Liu
Shaoyan Liu
Patient-based and region-based detection rates

17 June 2026
Verified
Other
Open access
ZKZiren Kong
Ziren Kong
ZLZhu Li
Zhu Li
XCXi-Yang Cui
Xi-Yang Cui
JWJian Wang
Jian Wang
MXMengxin Xu
Mengxin Xu
SLShaoyan Liu
Shaoyan Liu
Correlation between [68Ga]Ga-CTR-FAPI uptake and FAP expression